CRIS · Curis Inc
$4.98
+0.15 (+3.11%)
At close · Jul 29
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued.”View the 10-Q filed May 13, 2026
Market Cap
$188.27M
Shares
38.98M
Curis Inc Earnings Call Transcripts
Every quarterly earnings call for Curis Inc (CRIS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲4.7%
$2.39M
−$15.94M
'22 Q2
22-08-04
▼7%
$2.83M
−$13.29M
'22 Q3
22-11-09
▼7.9%
$2.89M
−$11.33M
'22 Q4
23-03-13
▲11.7%
$2.30M
−$11.56M
'23 Q1
23-05-04
▼8.2%
$2.20M
−$11.96M
'23 Q2
23-08-03
▲0.3%
$2.83M
−$12.18M
'23 Q3
23-11-02
▼6.6%
$2.70M
−$11.71M
'23 Q4
24-02-08
▼9.2%
$2.09M
−$11.88M
'24 Q1
24-05-07
▲15.9%
$2.55M
−$11.80M
'24 Q2
24-08-01
▲3.5%
$2.93M
−$10.09M
'24 Q3
24-11-14
▲24.1%
$3.35M
−$9.62M
'24 Q4
25-03-31
▲14.1%
$2.38M
−$10.62M
'25 Q1
25-05-06
▲8%
$2.75M
−$8.59M
'25 Q2
25-08-05
▲8.4%
$3.18M
−$7.73M
'25 Q3
25-11-06
▼66%
$1.14M
$19.36M
'25 Q4
26-03-19
LATEST
▼100%
$
−$24.20M
'26 Q1
26-05-12
Earnings call
FY26 · Q1
2026-05-12
Curis Inc Q1 FY2026 Earnings Call
Positive tone
TakeAim CLL proof-of-concept study
TakeAim Lymphoma / PCNSL registrational study
Emavusertib differentiation in CLL
Revenue
$
▼ 100% YoY Diluted EPS
$-25.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Curis Inc Q4 FY2025 Earnings Call
Confident tone
CLL Proof-of-Concept Study
PCNSL Registrational Study (TakeAim Lymphoma)
Emavusertib Dual Pathway Mechanism
Revenue
$1.14M*
▼ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Curis Inc Q3 FY2025 Earnings Call
Positive tone
CLL Program Expansion
AML Triplet Study (Aza-Ven + Emavusertib)
PCNSL (Primary CNS Lymphoma) TakeAim Lymphoma Study
Revenue
$3.18M
▲ 8.4% YoY Diluted EPS
$-9.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Curis Inc Q2 FY2025 Earnings Call
Confident tone
TakeAim Lymphoma / PCNSL study
Frontline AML triplet study
CLL proof-of-concept study
Revenue
$2.75M
▲ 8% YoY Diluted EPS
$-13.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Curis Inc Q1 FY2025 Earnings Call
Positive tone
Emavusertib in PCNSL (TakeAim Lymphoma study)
Emavusertib in AML
Regulatory pathway / FDA and EMA engagement
Revenue
$2.38M
▲ 14.1% YoY Diluted EPS
$-25.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Curis Inc Q4 FY2024 Earnings Call
Revenue
$3.35M*
▲ 24.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Curis Inc Q3 FY2024 Earnings Call
Positive tone
PCNSL study with ibrutinib combination
FDA regulatory engagement and accelerated approval
TakeAim Leukemia (AML) data
Revenue
$2.93M
▲ 3.5% YoY Diluted EPS
$-34.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Curis Inc Q2 FY2024 Earnings Call
Confident tone
TakeAim Leukemia study in AML
TakeAim Lymphoma / PCNSL study
IRAK4 mechanism and differentiation
Revenue
$2.55M
▲ 15.9% YoY Diluted EPS
$-40.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Curis Inc Q1 FY2024 Earnings Call
Confident tone
FLT3 mutation benchmark positioning
Emavusertib clinical progress in AML and lymphoma
Regulatory path and FDA discussions
Revenue
$2.09M
▼ 9.2% YoY Diluted EPS
$-41.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-08
Curis Inc Q4 FY2023 Earnings Call
Confident tone
Emavusertib leukemia program (AML)
Solid tumor expansion (melanoma/IIT)
Primary CNS lymphoma (PCNSL) program
Revenue
$2.70M*
▼ 6.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Curis Inc Q3 FY2023 Earnings Call
Revenue
$2.83M
▲ 0.3% YoY Diluted EPS
$-42.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Curis Inc Q2 FY2023 Earnings Call
Revenue
$2.20M
▼ 8.2% YoY Diluted EPS
$-49.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Curis Inc Q1 FY2023 Earnings Call
Revenue
$2.30M
▲ 11.7% YoY Diluted EPS
$-47.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Curis Inc Q4 FY2022 Earnings Call
Revenue
$2.89M*
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Curis Inc Q3 FY2022 Earnings Call
Revenue
$2.83M
▼ 7% YoY Diluted EPS
$-56.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Curis Inc Q2 FY2022 Earnings Call
Revenue
$2.39M
▲ 4.7% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Curis Inc Q1 FY2022 Earnings Call
Revenue
$2.06M
▼ 6% YoY Diluted EPS
$-3.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Curis Inc Q4 FY2021 Earnings Call
Revenue
$3.13M*
▲ 3.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Curis Inc Q3 FY2021 Earnings Call
Revenue
$3.04M
▲ 10.8% YoY Diluted EPS
$-2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Curis Inc Q2 FY2021 Earnings Call
Revenue
$2.29M
▼ 3.1% YoY Diluted EPS
$-2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Curis Inc Q1 FY2021 Earnings Call
Revenue
$2.19M
▼ 19.2% YoY Diluted EPS
$-2.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Curis Inc Q4 FY2020 Earnings Call
Revenue
$3.02M
▼ 8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Curis Inc Q3 FY2020 Earnings Call
Revenue
$2.74M
▼ 4% YoY Diluted EPS
$-2.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Curis Inc Q2 FY2020 Earnings Call
Revenue
$2.36M
▲ 12.7% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Curis Inc Q1 FY2020 Earnings Call
Revenue
$2.71M
▲ 53.3% YoY Diluted EPS
$-5.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-19
Curis Inc Q4 FY2019 Earnings Call
Revenue
$3.29M
▲ 19.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls